DoriVac is a revolutionary vaccine platform developed by researchers at Harvard’s Wyss Institute that uses DNA origami technology to create self-assembling nanostructures as vaccine scaffolds. Unlike traditional vaccines or mRNA-based approaches, DoriVac folds a single strand of DNA into a precise square-block nanoparticle that can carry both antigens and adjuvants in specific arrangements. This modular design allows researchers to customize the immune response by changing what molecules are attached to the DNA scaffold, potentially targeting multiple diseases from a single platform.

How does DNA origami work in vaccines?

DNA origami is a technique where a long single strand of DNA is folded into a predetermined three-dimensional shape using hundreds of short complementary DNA strands called staples. In DoriVac, this creates a square-block nanoparticle approximately 50 nanometers in size. One face of the block carries disease-specific antigens that teach the immune system what to target, while the other face carries adjuvants that boost the immune response. The precise spatial arrangement of these components is key to generating strong and targeted immunity.

How does DoriVac compare to mRNA vaccines?

DoriVac offers several potential advantages over mRNA vaccine technology. While mRNA vaccines like those from Pfizer and Moderna require ultra-cold storage at negative 20 to negative 70 degrees Celsius, DoriVac nanostructures remain stable at room temperature, eliminating cold-chain logistics challenges. Both platforms generate comparable immune responses in preclinical studies. Additionally, DoriVac’s modular design makes it easier to swap antigens for different diseases without redesigning the entire delivery system, potentially enabling faster response to new pathogens.

What diseases can DoriVac target?

The DoriVac platform has demonstrated promising results targeting multiple diseases by focusing on the conserved HR2 peptide region found across various viral families. In the study published in Nature Biomedical Engineering in March 2026, researchers showed the platform could generate immune responses against COVID-19 coronavirus variants, HIV, and Ebola virus. The ability to target conserved viral regions means DoriVac vaccines could potentially provide broader protection against future viral mutations and emerging variants.

When will DoriVac be available to the public?

DoriVac is currently in the preclinical research stage following its March 2026 publication in Nature Biomedical Engineering by the Harvard Wyss Institute team. Before reaching the public, the technology must undergo Phase 1, 2, and 3 clinical trials to demonstrate safety and efficacy in humans. This process typically takes five to ten years, though it could be accelerated under emergency use authorization if needed during a pandemic. The Wyss Institute is exploring partnerships with pharmaceutical companies to advance clinical development of the platform.

Health · BiotechMarch 2026

DoriVac: DNA Origami Vaccines Could Replace mRNA

Harvard’s DoriVac vaccine platform uses folded DNA nanostructures to deliver immune responses comparable to mRNA vaccines while being stable without cold storage.

DNA OrigamiWyss InstituteHarvardVaccines

GEN News | DoriVac DNA origami nanostructure from Wyss Institute

Platform

DoriVac

Size

~50 nm

Targets

COVID, HIV, Ebola

Storage

Room temp

What Is DoriVac?

DoriVac is a next-generation vaccine platform developed by researchers at Harvard University’s Wyss Institute. Instead of using mRNA to instruct cells to produce viral proteins like the Pfizer or Moderna vaccines, DoriVac uses DNA origami technology to fold a long strand of DNA into a square-block nanostructure approximately 50 nanometers in size.

This nanostructure functions as a smart vaccine scaffold: one face of the square block carries disease-specific antigens, while the other face carries adjuvants that stimulate the immune system. This precise spatial arrangement allows unprecedented control over the immune response.

The research, published in March 2026 in Nature Biomedical Engineering, demonstrates that DoriVac generates immune responses comparable to mRNA vaccines in preclinical studies while addressing one of mRNA vaccines’ biggest challenges: the requirement for strict cold-chain storage.

DNA Origami Nanostructure

Adjuvant Face

CpG

~50 nm

DNA scaffold

Antigen Face

HR2 peptide

DoriVac square-block nanoparticle: one face carries adjuvants (CpG), the other carries antigens (HR2 peptide)

GEN News | DNA origami square block nanoparticle diagram

How It Works

The DoriVac process begins with a long strand of DNA engineered to self-fold into a specific shape when mixed with hundreds of short complementary DNA strands called staples. This self-assembly process occurs in a test tube without complex equipment, significantly reducing manufacturing costs.

The key innovation of DoriVac is its ability to target the conserved HR2 peptide region — a part of viruses that changes little across variants and different viral families. This means a single DoriVac vaccine could provide protection against multiple diseases, from COVID-19 to HIV and Ebola.

When injected into the body, DoriVac nanoparticles are recognized and processed by antigen-presenting cells, activating both innate and adaptive immune responses. The result is a strong and durable immune response without requiring cold storage.

Comparison: DoriVac vs mRNA Vaccines

Feature	DoriVac	mRNA
Temperature Stability	+Stable at room temperature	Requires -20°C to -70°C
Immune Response	Comparable to mRNA in preclinical studies	Current gold standard
Modular Design	+Easy antigen swapping	Requires sequence redesign
Manufacturing Cost	+Self-assembling, potentially lower cost	Complex manufacturing, higher cost
Development Stage	Preclinical (2026)	+Approved, widely deployed
Multi-disease Targeting	+COVID-19, HIV, Ebola from one platform	One sequence per disease

Neuroscience News | Medical research and biotech illustration

Global Health Impact

One of the biggest barriers to global vaccine distribution is the cold-chain requirement. Pfizer’s mRNA vaccine requires storage at negative 70 degrees Celsius, while Moderna requires negative 20 degrees. This makes distributing vaccines to rural areas in developing countries extremely difficult and costly.

DoriVac could change this equation. With stability at room temperature, DNA origami vaccines could be shipped and stored anywhere without specialized refrigeration. This is particularly important for countries in Africa, Southeast Asia, and South America where cold storage infrastructure is limited.

Furthermore, DoriVac’s modular design allows rapid vaccine adjustment when new virus variants emerge. Instead of redesigning the entire mRNA sequence, researchers simply change the antigens attached to the nanoparticle surface — a significantly faster and simpler process.

References

[1]DNA origami vaccines next leap beyond mRNAScienceDaily
[2]Beyond mRNA: DNA Origami as Vaccine PlatformSciTechDaily
[3]DoriVac TechnologyWyss Institute
[4]DNA Origami: the future of vaccines -- Nature Reviews, March 2026Nature Reviews

▸ mRNA vaccines require -70C storage -- DoriVac is stable at room temperature, potentially saving millions in rural Southeast Asia where specialized freezers don't exist.

▸ If DoriVac succeeds in clinical trials, vaccine production costs could drop 60-80% -- helping developing nations achieve vaccine independence faster.

Frequently Asked Questions

The most common questions about DoriVac vaccine technology and DNA origami.

By Mai Tran · Wellness & Lifestyle Editor

Published: March 19, 2026 · Updated: March 25, 2026

health·DoriVac vaccine · DNA origami vaccine · mRNA alternative · Wyss Institute